Pfizer, Medicus ink licensing deal worth up to $1B for antibody drug conjugate
Seeking Alpha News (Thu, 3-Sep 10:52 AM ET)
Medicus Pharma Secures Global Pfizer License for CD228V
TipRanks (Thu, 3-Sep 8:51 AM ET)
Quant Check: Top- and bottom-rated small-cap healthcare stocks post-earnings
Seeking Alpha News (Tue, 1-Sep 10:25 AM ET)
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
ACCESS Newswire (Wed, 12-Aug 6:00 PM ET)
Globe Newswire (Mon, 3-Aug 7:30 AM ET)
Globe Newswire (Fri, 31-Jul 7:30 AM ET)
Globe Newswire (Mon, 27-Jul 8:17 AM ET)
Globe Newswire (Thu, 16-Jul 7:30 AM ET)
Globe Newswire (Mon, 22-Jun 7:30 AM ET)
Globe Newswire (Mon, 15-Jun 7:30 AM ET)
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.
Medicus Pharma Ltd. trades on the NASDAQ stock market under the symbol MDCX.
As of September 4, 2026, MDCX stock price was flat at $0.17 with 10,683,471 million shares trading.
MDCX has a beta of 2.77, meaning it tends to be more sensitive to market movements. MDCX has a correlation of 0.04 to the broad based SPY ETF.
MDCX has a market cap of $10.87 million. This is considered a Sub-Micro Cap stock.
MDCX has underperformed the market in the last year with a price return of -90.6% while the SPY ETF gained +19.8%. MDCX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -54.0% and -36.7%, respectively, while the SPY returned +2.0% and +0.6%, respectively.
MDCX support price is $.16 and resistance is $.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MDCX shares will trade within this expected range on the day.
